183 related articles for article (PubMed ID: 24289205)
21. [Treatment of metastatic melanoma with BRAF inhibitors].
Hafner C
Hautarzt; 2011 Sep; 62(9):696-8. PubMed ID: 21863388
[No Abstract] [Full Text] [Related]
22. Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma.
Ravnan MC; Matalka MS
Clin Ther; 2012 Jul; 34(7):1474-86. PubMed ID: 22742884
[TBL] [Abstract][Full Text] [Related]
23. Altered Morphology and Immunohistochemical Characteristics in Metastatic Malignant Melanoma After Therapy With Vemurafenib.
Powell MR; Sheehan DJ; Kleven DT
Am J Dermatopathol; 2016 Sep; 38(9):e137-9. PubMed ID: 27541173
[TBL] [Abstract][Full Text] [Related]
24. Vemurafenib: in unresectable or metastatic melanoma.
Keating GM
BioDrugs; 2012 Oct; 26(5):325-34. PubMed ID: 22946753
[TBL] [Abstract][Full Text] [Related]
25. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
[TBL] [Abstract][Full Text] [Related]
26. Erythema nodosum in a patient undergoing vemurafenib therapy for metastatic melanoma.
Degen A; Völker B; Kapp A; Gutzmer R
Eur J Dermatol; 2013; 23(1):118. PubMed ID: 23419281
[No Abstract] [Full Text] [Related]
27. Leukocyte count restoration under dabrafenib treatment in a melanoma patient with vemurafenib-induced leukopenia: case report.
Orouji E; Ziegler B; Umansky V; Gebhardt C; Utikal J
Medicine (Baltimore); 2014 Dec; 93(28):e161. PubMed ID: 25526431
[TBL] [Abstract][Full Text] [Related]
28. Long-term stabilization of leptomeningeal disease with whole-brain radiation therapy in a patient with metastatic melanoma treated with vemurafenib: a case report.
Lee JM; Mehta UN; Dsouza LH; Guadagnolo BA; Sanders DL; Kim KB
Melanoma Res; 2013 Apr; 23(2):175-8. PubMed ID: 23358426
[TBL] [Abstract][Full Text] [Related]
29. Case series: indoor-photosensitivity caused by fluorescent lamps in patients treated with vemurafenib for metastatic melanoma.
Boudewijns S; Gerritsen WR; Koornstra RH
BMC Cancer; 2014 Dec; 14():967. PubMed ID: 25515496
[TBL] [Abstract][Full Text] [Related]
30. Vemurafenib-induced interface dermatitis manifesting as radiation-recall and a keratosis pilaris-like eruption.
Braunstein I; Gangadhar TC; Elenitsas R; Chu EY
J Cutan Pathol; 2014 Jun; 41(6):539-43. PubMed ID: 24517243
[TBL] [Abstract][Full Text] [Related]
31. Absent response of intracranial melanoma metastases harboring BRAF V600E sequence variation to vemurafenib.
D'Alonzo D; Glatz K
Mayo Clin Proc; 2013 Dec; 88(12):e151-2. PubMed ID: 24290130
[No Abstract] [Full Text] [Related]
32. The discovery of vemurafenib for the treatment of BRAF-mutated metastatic melanoma.
Kim A; Cohen MS
Expert Opin Drug Discov; 2016 Sep; 11(9):907-16. PubMed ID: 27327499
[TBL] [Abstract][Full Text] [Related]
33. Vemurafenib as a neoadjuvant therapy in advanced melanoma: local tumour control, but no prevention of metastatic relapse.
Tauber M; Pages C; La Selva R; Schneider P; Chardin J; Osio A; Mourah S; Culine S; Vercellino L; Bagot M; Lebbé C
Eur J Dermatol; 2013; 23(5):702-3. PubMed ID: 24135270
[No Abstract] [Full Text] [Related]
34. A case of vemurafenib-induced keratosis pilaris-like eruption.
Wang CM; Fleming KF; Hsu S
Dermatol Online J; 2012 Apr; 18(4):7. PubMed ID: 22559022
[TBL] [Abstract][Full Text] [Related]
35. Induction vemurafenib followed by consolidative radiation therapy for surgically incurable melanoma.
Seeley AR; De Los Santos JF; Conry RM
Melanoma Res; 2015 Jun; 25(3):246-51. PubMed ID: 25746037
[TBL] [Abstract][Full Text] [Related]
36. BRAF(V600) mutation levels predict response to vemurafenib in metastatic melanoma.
Lebbé C; How-Kit A; Battistella M; Sadoux A; Podgorniak MP; Sidina I; Pages C; Roux J; Porcher R; Tost J; Mourah S
Melanoma Res; 2014 Aug; 24(4):415-8. PubMed ID: 24933605
[No Abstract] [Full Text] [Related]
37. Vemurafenib-associated gingival hyperplasia in patient with metastatic melanoma.
Mangold AR; Bryce A; Sekulic A
J Am Acad Dermatol; 2014 Nov; 71(5):e205-6. PubMed ID: 25437992
[No Abstract] [Full Text] [Related]
38. A single-arm, open-label, expanded access study of vemurafenib in patients with metastatic melanoma in the United States.
Flaherty L; Hamid O; Linette G; Schuchter L; Hallmeyer S; Gonzalez R; Cowey CL; Pavlick A; Kudrik F; Curti B; Lawson D; Chapman PB; Margolin K; Ribas A; McDermott D; Flaherty K; Cranmer L; Hodi FS; Day BM; Linke R; Hainsworth J
Cancer J; 2014; 20(1):18-24. PubMed ID: 24445759
[TBL] [Abstract][Full Text] [Related]
39. BRAF inhibitors-induced panniculitis: a cutaneous side effect mimicking subcutaneous melanoma metastasis.
Chaminade A; Conte H; Jouary T; Fauconneau A; Darrigade AS; Beylot-Barry M; Pham-Ledard A
J Eur Acad Dermatol Venereol; 2015 Feb; 29(2):392-393. PubMed ID: 24533578
[No Abstract] [Full Text] [Related]
40. Vemurafenib-induced eccrine squamous syringometaplasia.
Lescoat A; Droitcourt C; Stock N; Le Gall F; Dupuy A
Dermatology; 2013; 226(4):362-4. PubMed ID: 23860306
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]